Brief: Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation From US FDA For BMS-986446 For Treatment Of Alzheimer's Disease
01/10/2025 21:59
Oct 1 (Reuters) - Prothena Corporation PLC PRTA.O: PROTHENA’S PARTNER BRISTOL MYERS SQUIBB OBTAINS FAST TRACK DESIGNATION FROM THE U.S. FDA FOR BMS-986446 (PRX005), AN ANTI-MTBR-TAU-TARGETING ANTIBODY, FOR THE TREATMENT OF ALZHEIMER’S DISEASE Source text: ID:nBw62jkWYa Further company coverage: PRTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prothena
See all newsProthena Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Prothena's Q2 net loss narrows on lower expenses
Brief: Prothena Q2 Net Income USD -18.583 Million
Prothena Corporation PLC expected to post a loss of 39 cents a share - Earnings Preview
Prothena posts Q1 revenue surge fueled by $50 million Novo Nordisk milestone payment